Literature DB >> 15958547

In vitro modeling of human pancreatic duct epithelial cell transformation defines gene expression changes induced by K-ras oncogenic activation in pancreatic carcinogenesis.

Jiaying Qian1, Jiangong Niu, Ming Li, Paul J Chiao, Ming-Sound Tsao.   

Abstract

Genetic analysis of pancreatic ductal adenocarcinomas and their putative precursor lesions, pancreatic intraepithelial neoplasias (PanIN), has shown a multistep molecular paradigm for duct cell carcinogenesis. Mutational activation or inactivation of the K-ras, p16(INK4A), Smad4, and p53 genes occur at progressive and high frequencies in these lesions. Oncogenic activation of the K-ras gene occurs in >90% of pancreatic ductal carcinoma and is found early in the PanIN-carcinoma sequence, but its functional roles remain poorly understood. We show here that the expression of K-ras(G12V) oncogene in a near diploid HPV16-E6E7 gene immortalized human pancreatic duct epithelial cell line originally derived from normal pancreas induced the formation of carcinoma in 50% of severe combined immunodeficient mice implanted with these cells. A tumor cell line established from one of these tumors formed ductal cancer when implanted orthotopically. These cells also showed increased activation of the mitogen-activated protein kinase, AKT, and nuclear factor-kappaB pathways. Microarray expression profiling studies identified 584 genes whose expression seemed specifically up-regulated by the K-ras oncogene expression. Forty-two of these genes have been reported previously as differentially overexpressed in pancreatic cancer cell lines or primary tumors. Real-time PCR confirmed the overexpression of a large number of these genes. Immunohistochemistry done on tissue microarrays constructed from PanIN and pancreatic cancer samples showed laminin beta3 overexpression starting in high-grade PanINs and occurring in >90% of pancreatic ductal carcinoma. The in vitro modeling of human pancreatic duct epithelial cell transformation may provide mechanistic insights on gene expression changes that occur during multistage pancreatic duct cell carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15958547     DOI: 10.1158/0008-5472.CAN-04-3208

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  61 in total

1.  KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma.

Authors:  Jianhua Ling; Ya'an Kang; Ruiying Zhao; Qianghua Xia; Dung-Fang Lee; Zhe Chang; Jin Li; Bailu Peng; Jason B Fleming; Huamin Wang; Jinsong Liu; Ihor R Lemischka; Mien-Chie Hung; Paul J Chiao
Journal:  Cancer Cell       Date:  2012-01-17       Impact factor: 31.743

2.  A novel small-molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo.

Authors:  Kuzhuvelil B Harikumar; Ajaikumar B Kunnumakkara; Nobuo Ochi; Zhimin Tong; Amit Deorukhkar; Bokyung Sung; Lloyd Kelland; Stephen Jamieson; Rachel Sutherland; Tony Raynham; Mark Charles; Azadeh Bagherzadeh; Azadeh Bagherazadeh; Caroline Foxton; Alexandra Boakes; Muddasar Farooq; Dipen Maru; Parmeswaran Diagaradjane; Yoichi Matsuo; James Sinnett-Smith; Juri Gelovani; Sunil Krishnan; Bharat B Aggarwal; Enrique Rozengurt; Christopher R Ireson; Sushovan Guha
Journal:  Mol Cancer Ther       Date:  2010-05-04       Impact factor: 6.261

3.  Manganoporphyrins and ascorbate enhance gemcitabine cytotoxicity in pancreatic cancer.

Authors:  John A Cieslak; Robert K Strother; Malvika Rawal; Juan Du; Claire M Doskey; Samuel R Schroeder; Anna Button; Brett A Wagner; Garry R Buettner; Joseph J Cullen
Journal:  Free Radic Biol Med       Date:  2015-02-26       Impact factor: 7.376

4.  IL-6 stimulates STAT3 and Pim-1 kinase in pancreatic cancer cell lines.

Authors:  Katherine M Block; Neale T Hanke; Erin A Maine; Amanda F Baker
Journal:  Pancreas       Date:  2012-07       Impact factor: 3.327

5.  In vitro models of pancreatic cancer for translational oncology research.

Authors:  Georg Feldmann; Sherri Rauenzahn; Anirban Maitra
Journal:  Expert Opin Drug Discov       Date:  2009-04-01       Impact factor: 6.098

6.  Targeting eNOS in pancreatic cancer.

Authors:  Benjamin L Lampson; S Disean Kendall; Brooke B Ancrile; Meghan M Morrison; Michael J Shealy; Katharine S Barrientos; Matthew S Crowe; David F Kashatus; Rebekah R White; Susan B Gurley; Diana M Cardona; Christopher M Counter
Journal:  Cancer Res       Date:  2012-06-27       Impact factor: 12.701

7.  Extracellular superoxide dismutase suppresses hypoxia-inducible factor-1α in pancreatic cancer.

Authors:  Zita A Sibenaller; Jessemae L Welsh; Changbin Du; Jordan R Witmer; Hannah E Schrock; Juan Du; Garry R Buettner; Prabhat C Goswami; John A Cieslak; Joseph J Cullen
Journal:  Free Radic Biol Med       Date:  2014-02-07       Impact factor: 7.376

8.  Transformation by oncogenic Ras expands the early genomic response to transforming growth factor beta in intestinal epithelial cells.

Authors:  Carl E Allen; Jianguo Du; Bo Jiang; Qin Huang; Adam J Yakovich; John A Barnard
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

9.  Bmi1 combines with oncogenic KRAS to induce malignant transformation of human pancreatic duct cells in vitro.

Authors:  Shao-Jie Chen; Yin-Ting Chen; Lin-Juan Zeng; Qiu-Bo Zhang; Guo-da Lian; Jia-Jia Li; Ke-Ge Yang; Chu-Mei Huang; Ya-Qing Li; Zhong-Hua Chu; Kai-Hong Huang
Journal:  Tumour Biol       Date:  2016-03-08

10.  KLF4 Is Essential for Induction of Cellular Identity Change and Acinar-to-Ductal Reprogramming during Early Pancreatic Carcinogenesis.

Authors:  Daoyan Wei; Liang Wang; Yongmin Yan; Zhiliang Jia; Mihai Gagea; Zhiwei Li; Xiangsheng Zuo; Xiangyu Kong; Suyun Huang; Keping Xie
Journal:  Cancer Cell       Date:  2016-03-14       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.